Recombinant Anti-NUB1 antibody [EPR10716] (ab171077)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR10716] to NUB1
- Suitable for: Flow Cyt (Intra), WB, ICC/IF
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-NUB1 antibody [EPR10716]
See all NUB1 primary antibodies -
Description
Rabbit monoclonal [EPR10716] to NUB1 -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt (Intra), WB, ICC/IFmore details
Unsuitable for: IHC-P or IP -
Species reactivity
Reacts with: Human
Does not react with: Mouse, Rat -
Immunogen
Synthetic peptide within Human NUB1 aa 1-100 (Cysteine residue). The exact sequence is proprietary.
Database link: Q9Y5A7 -
Positive control
- Raji, SHSY5Y, 293T and HeLa cell line lysates. HeLa cells. Permeabilized Raji cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR10716 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab171077 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/1000 - 1/5000. Predicted molecular weight: 71 kDa.
|
|
ICC/IF |
1/100 - 1/250.
|
Notes |
---|
Flow Cyt (Intra)
1/10 - 1/100. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/1000 - 1/5000. Predicted molecular weight: 71 kDa. |
ICC/IF
1/100 - 1/250. |
Target
-
Function
Specific down-regulator of the NEDD8 conjugation system. Recruits NEDD8, UBD, and their conjugates to the proteasome for degradation. Isoform 1 promotes the degradation of NEDD8 more efficiently than isoform 2. -
Tissue specificity
Widely expressed with lowest expression in the pancreas for isoform 1 and in leukocytes, liver, prostate and skeletal muscle for isoform 2. -
Sequence similarities
Contains 3 UBA domains. -
Cellular localization
Nucleus. Predominantly nuclear. - Information by UniProt
-
Database links
- Entrez Gene: 51667 Human
- Omim: 607981 Human
- SwissProt: Q9Y5A7 Human
- Unigene: 647082 Human
-
Alternative names
- BS4 antibody
- NEDD8 ultimate buster 1 antibody
- Negative regulator of ubiquitin like proteins 1 antibody
see all
Images
-
All lanes : Anti-NUB1 antibody [EPR10716] (ab171077) at 1/1000 dilution
Lane 1 : Raji cell lysate
Lane 2 : SH-SY5Y cell lysate
Lane 3 : 293T (Human embryonic kidney epithelial cell) cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 71 kDa -
Immunofluorescent staining of HeLa cells labeling NUB1 using ab171077 at 1/100 dilution.
-
Intracellular flow cytometric analysis of permeabilized Raji cells labeling NUB1 using ab171077 at 1/10 dilution (red) or a rabbit IgG negative (green).
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab171077 has not yet been referenced specifically in any publications.